Table 1.
Clinical and demographic characteristics of patients
| Variable | Total sample | Responsive 1 and 2 | Unresponsive |
|---|---|---|---|
| (N = 463) | (N = 432) | (N = 31) | |
| Age (years) | 67.9 ± 16.1 | 67.5 ± 16.07 | 74.32 ± 15.14* |
| Gender (F:M) | 198:265 | 12:19 | 186:146 |
| Medical diagnosis | |||
| Clinical | 47.1 | 47.0 | 51.6 |
| Surgical | 52.9 | 53.0 | 48.4 |
| APACHE IV score | 38.2 ± 13.8 | 37.77 ± 18.83 | 44.54 ± 11.95* |
| Primary diagnosis on ICU admission | |||
| Cancer | 125 (27.0) | 115 (26.6) | 10 (32.2) |
| Sepsis/septic shock | 68 (14.7) | 64 (14.8) | 4 (12.9) |
| Heart disease | 45 (9.7) | 42 (9.7) | 3 (9.7) |
| Exacerbated COPD | 24 (5.2) | 22 (5.1) | 2 (6.4) |
| AFR | 23 (5.0) | 21 (4.9) | 2 (6.4) |
| Infections/infectious diseases | 16 (3.5) | 15 (3.5) | 1 (3.2) |
| Kidney failure | 6 (1.3) | 5 (1.2) | 1 (3.2) |
| Thoracic surgery | 62 (13.4) | 56 (13.0) | 6 (19.3) |
| Abdominal surgery | 141 (30.5) | 130 (30.1) | 11 (35.5) |
| Various surgeries | 42 (9.1) | 39 (9.0) | 3 (9.7) |
| Others | 59 (12.7) | 54 (12.5) | 5 (16.1) |
| Use of invasive MV | 12.1 | 11.34 | 22.6 |
| Time of invasive MV (days) | 5.4 ± 5.7 | 4.7 ± 5.1 | 10.3 ± 7.3* |
| Use of sedation | 13.2 | 12.0 | 22.6 |
| Time of sedation (days) | 5.6 ± 5.8 | 5.0 ± 5.0 | 11.6 ± 8.6* |
| Use of VAD | 61.5 | 63 | 48.4 |
| Time of VAD (days) | 4.3 ± 4.1 | 4.1 ± 3.8 | 8.4 ± 6.5* |
| Use of continuous analgesia | 14.9 | 14.8 | 16.1 |
| Time of continuous analgesia (days) | 2.8 ± 1.4 | 2.8 ± 1.38 | 2.4 ± 0.9 |
| Use of intermittent analgesia | 68.9 | 74.2 | 68.5 |
| ICU stay (days) | 5.5 ± 5.7 | 5.26 ± 5.07 | 8.5 ± 10.9* |
| Hospital stay (days) | 20.5 ± 28.5 | 19.6 ± 27.9 | 32.81 ± 33.98* |
F - female; M - male; APACHE - Acute Physiology and Chronic Health Evaluation; COPD - chronic obstructive pulmonary disease; AFR - acute respiratory failure; MV - mechanical ventilation; VAD - vasoactive drugs; ICU - intensive care unit. The results are expressed as numbers (%) or means ± standard deviations.
*
p < 0.05 compared to responsive 1 and 2.